血清CA125和HE4水平作为晚期上皮性卵巢癌患者新辅助铂类化疗后最佳间隔手术和铂敏感性的预测指标。
Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer.
作者信息
Pelissier Aurélie, Roulot Aurélie, Guéry Béatrice, Bonneau Claire, Bellet Dominique, Rouzier Roman
机构信息
Department of Breast and Gynecological Surgery, Centre René Huguenin, Institut Curie, 35 rue Dailly, 92210, Saint Cloud, France.
Versailles-St-Quentin-en-Yvelines University, EA 7285: Risques cliniques et sécurité en santé des femmes et en santé périnatale, Versailles, France.
出版信息
J Ovarian Res. 2016 Sep 27;9(1):61. doi: 10.1186/s13048-016-0270-7.
BACKGROUND
The aim of this study is to evaluate a new tumour marker, HE4, and to compare it with CA125 in predicting optimal cytoreduction and response to chemotherapy. Thirty patients with advanced epithelial ovarian cancer and multiple sera harvested during neoadjuvant chemotherapy (NAC) were included.
RESULTS
Based on ROC curves analysis, CA125 ≤ 75 UI/ml and HE4 ≤ 252 pmol/L after the 3rd cycles of NAC, with a sensitivity of 93.7 % and a specificity of 92.3 % (PPV = 93.7 % and NPV = 92.3 %), offered the best combination for predicting optimal cytoreduction. In addition, the HE4 value of 115 pmol/L is the best cut-off level for identifying platinum-sensitive patients.
CONCLUSIONS
The introduction of HE4 as a new tool for predicting platinum-sensitivity and interval optimal cytoreduction is promising.
背景
本研究旨在评估一种新的肿瘤标志物人附睾蛋白4（HE4），并将其与癌抗原125（CA125）在预测最佳肿瘤细胞减灭术及化疗反应方面进行比较。纳入了30例晚期上皮性卵巢癌患者以及新辅助化疗（NAC）期间采集的多份血清样本。
结果
基于受试者工作特征（ROC）曲线分析，NAC第3周期后CA125≤75 UI/ml且HE4≤252 pmol/L，预测最佳肿瘤细胞减灭术的敏感性为93.7%，特异性为92.3%（阳性预测值=93.7%，阴性预测值=92.3%），这是预测最佳肿瘤细胞减灭术的最佳组合。此外，115 pmol/L的HE4值是识别铂敏感患者的最佳临界值。
结论
引入HE4作为预测铂敏感性和间期最佳肿瘤细胞减灭术的新工具很有前景。
Zotero 插件